Polatuzumab vedotin, rituximab, and bendamustine combination in relapsed or refractory diffuse large B-cell lymphoma: A real-world data from Turkey

Basit Öğe Kaydı
dc.authorid0000-0002-2035-9462
dc.authorid0000-0003-1237-8281
dc.contributor.authorDal, Mehmet Sinan
dc.contributor.authorUlu, Bahar Uncu
dc.contributor.authorUzay, Ant
dc.contributor.authorAkay, Olga Meltem
dc.contributor.authorBeşışık, Sevgi
dc.contributor.authorYenerel, Mustafa Nuri
dc.contributor.authorÇelik, Serhat
dc.contributor.authorKaynar, Leylagül
dc.contributor.authorYücel, Orhan Kemal
dc.contributor.authorDeveci, Burak
dc.contributor.authorSönmez, Mehmet
dc.contributor.authorMehtap, Özgür
dc.contributor.authorBeköz, Hüseyin Saffet
dc.contributor.authorSunu, Cenk
dc.contributor.authorSalim, Ozan
dc.contributor.authorUlaş, Turgay
dc.contributor.authorKartı, Sami
dc.contributor.authorAltuntaş, Fevzi
dc.contributor.authorFerhanoğlu, Burhan
dc.contributor.authorTuğlular, Tülin Fırat
dc.date.accessioned2023-02-23T12:36:44Z
dc.date.available2023-02-23T12:36:44Z
dc.date.issued2023
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.description.abstractPolatuzumab vedotin (Pola) with bendamustine and rituximab (BR) is a promising option for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). We analyzed the data of 71 R/R DLBCL patients who had been treated with Pola-BR in the named patient program from March 2018 to April 2021 from 32 centers in Turkey. All patients received up to six cycles of Pola 1.8 mg/kg, rituximab 375 mg/m2 on day 1, and bendamustine 90 mg/m2 on days 1–2 of each cycle. Median age at Pola-BR initiation was 55 (19–84). The overall response rate was 47.9%, including 32.4% CR rate when a median of 3 cycles was applied. With a median follow-up of 5 months, the median OS was 5 months. Grade 3–4 neutropenia and thrombocytopenia were the most common hematological toxicities. The real-world data from our cohort showed the Pola-BR is an effective option with a manageable toxicity profile.
dc.identifier.citationDal, M. S., Ulu, B. U., Uzay, A., Akay, O. M., Beşışık, S., Yenerel, M. N. ... Tuğlular, T. F. (2023). Polatuzumab vedotin, rituximab, and bendamustine combination in relapsed or refractory diffuse large B-cell lymphoma: A real-world data from Turkey. Annals of Hematology, 102(1), 133-140. https://doi.org/10.1007/s00277-022-05052-x
dc.identifier.doi10.1007/s00277-022-05052-x
dc.identifier.endpage140
dc.identifier.issn0939-5555
dc.identifier.issn1432-0584
dc.identifier.issue1
dc.identifier.pmid36401621
dc.identifier.scopus2-s2.0-85142265282
dc.identifier.scopusqualityQ1
dc.identifier.startpage133
dc.identifier.urihttps://doi.org/10.1007/s00277-022-05052-x
dc.identifier.urihttps://hdl.handle.net/20.500.12511/10517
dc.identifier.volume102
dc.identifier.wos000885401400002en_US
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorKaynar, Leylagül
dc.institutionauthorBeköz, Hüseyin Saffet
dc.language.isoen
dc.publisherSpringer
dc.relation.ispartofAnnals of Hematologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectBendamustine
dc.subjectDiffuse Large B-cell Lymphoma
dc.subjectPolatuzumab Vedotin
dc.subjectRefractory
dc.subjectRelapsed
dc.subjectRituximab
dc.titlePolatuzumab vedotin, rituximab, and bendamustine combination in relapsed or refractory diffuse large B-cell lymphoma: A real-world data from Turkey
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Kaynar-Leylagül-2023.pdf
Boyut:
653.3 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu